Proportions of CD1c+ and CD141+ cDC, and to a lower extent pDC, were markedly reduced in the PB of 31 patients with RA recruited prior to initiating treatment and compared with 30 healthy controls (HC) including 13 age- and sex-matched individuals (Supplemental Figure 1, A and B, and Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.152886DS1), in line with previous studies (25). This evidence concerns the gene CD1C and rheumatoid arthritis.